ENSC - Ensysce Biosciences, Inc.
IEX Last Trade
9.5
-0.600 -6.316%
Share volume: 0
Last Updated: Thu 26 Dec 2024 03:17:49 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
3.82%
PREVIOUS CLOSE
CHG
CHG%
$10.10
-0.60
-5.94%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
23.21%
1 Month
1,984.38%
3 Months
3,248.99%
6 Months
1,896.00%
1 Year
859.62%
2 Year
1,285.92%
Key data
Stock price
$9.50
DAY RANGE
N/A - N/A
52 WEEK RANGE
$0.17 - $10.96
52 WEEK CHANGE
$859.62
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: D. Lynn Kirkpatrick, PhD
Region: US
Website: ensysce.com
Employees: 10
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: ensysce.com
Employees: 10
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Ensysce Biosciences, Inc. engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended. release prodrugs of amphetamine for ADHD medication abuse.
Recent news